N/A
Completed N=1,493
Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients
Arthritis, Rheumatoid
Source: ClinicalTrials.gov NCT04428424 ↗
Enrolled (actual)
1,493
Serious AEs
—
Results posted
Sep 2021
Primary outcomePrimary: Disease Activity Score 28 (DAS28) in Participants With Positive Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12) — 3.13; 3.1 units on a scale
Summary
This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic citrullinated peptide using data from the Baghdad Teaching Hospital registry.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Disease Activity Score 28 (DAS28) in Participants With Positive Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12) |
3.13; 3.1 | — |
| PRIMARY Clinical Disease Activity Index (CDAI) Score in Participants With Positive Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12) |
8.0; 8.2 | — |
| PRIMARY Disease Activity Score 28 (DAS28) in Participants With Negative Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12) |
3.10; 3.16 | — |
| PRIMARY Clinical Disease Activity Index (CDAI) Score in Participants With Negative Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12) |
7.3; 6.8 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosed RA patients.
-≥18 years of age
- Did not receive previous another biological treatment
Exclusion Criteria
- Had previous biological treatment
- Use of etanercept for less than 1 year
Data sourced from ClinicalTrials.gov (NCT04428424). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.